Multiple sclerosis relapse

7 trials 1 recruiting MedDRA PT
7 Registered trials
1 Recruiting
3 Unique sponsors
10 Unique IMPs
7 Commercial trials
Drug classes (ATC)
H Endocrinology (ATC H) 2
L Oncology (ATC L) 6
N Neurology/Psychiatry (ATC N) 2
R Respiratory (ATC R) 2
— ATC code not specified 1
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Vaccine 2 substances
Corticosteroid 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Analgesic / antipyretic 1 substance
Monoclonal antibody (human) 1 substance
Phase III: 6 Phase IV: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

6 trials
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506467-34-00 10 countries 2020 n=357
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506543-41-00 14 countries 2018 n=645
    Ended
  • H e x a l AG Commercial
    IMP not specified
    2024-512319-40-00 3 countries 2025 n=126
    Ended
  • Novartis Pharma AG Commercial
    RECOMBINANT INTERFERON BETA-1B
    2023-507431-37-00 4 countries 2021 n=186
    Ended
  • Novartis Pharma AG Commercial
    OFATUMUMAB
    2023-507493-41-00 8 countries 2020 n=293
    Ended
  • Novartis Pharma AG Commercial
    B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE), B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021), A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE), A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN (A/GEORGIA/12/2022 CVR-167); DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE; OFATUMUMAB; PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE; PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A
    2023-507906-15-00 21 countries 2019 n=963
    Ended

Phase IV

1 trial
  • Novartis Pharma AG Commercial
    OFATUMUMAB
    2023-505283-11-00 4 countries 2024 n=15
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 4 Phase III, Phase IV 1
F. Hoffmann-La Roche AG Commercial 2 Phase III 0
H e x a l AG Commercial 1 Phase III 0
New trials by year
2019
1
2020
2
2021
1
2024
1
2025
1
← All indication landscapes